Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Metastasis | Research

Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center

Authors: Vinod Sharma, Atul Sharma, Vinod Raina, Deepak Dabkara, Bidhu Kalyan Mohanti, N. K. Shukla, Sushmita Pathy, Sanjay Thulkar, S. V. S. Deo, Sunil Kumar, Ranjit Kumar Sahoo

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

No data exist for the long-term outcome of metastatic colorectal cancer (mCRC) from the Southern part of Asia. The primary objective of the study is to evaluate the survival outcome of mCRC from an Indian tertiary care center. The study also aims to highlight the treatment pattern practiced and the unique clinico-pathologic characteristics.

Methods

This is a single-center retrospective observational study done at a large referral tertiary care center in North India. All patients with synchronous or metachronous mCRC who received at least one dose of chemotherapy for metastatic disease, registered between 2003 to 2017 were included. Primary outcome measures were overall survival and progression-free survival and prognostic factors of overall survival. Descriptive analysis was done for the clinicopathological characteristics and treatment patterns. Kaplan Meier method for overall survival and progression-free survival. Cox regression analysis was performed for the determination of the prognostic factors for overall survival.

Result

Out of 377 eligible patients, 256 patients (68%) had de novo metastatic disease and the remaining 121 (32%) progressed to metastatic disease after initial treatment. The cohort was young (median age, 46 years) with the most common primary site being the rectum. A higher proportion of signet (9%) and mucinous histology (24%). The three common sites of metastasis were the liver, peritoneum, and lung. In the first line, most patients received oxaliplatin-based chemotherapy (70%). Only 12.5% of patients received biologicals in the first-line setting. The median follow-up and median overall survival of study cohort were 17 months and 18.5 months. The factors associated with poor outcome for overall survival on multivariate analysis were ECOG performance status of > 1, high CEA, low albumin, and the number of lines of chemotherapy received (< 2).

Conclusion

The outcome of mCRC is inferior to the published literature. We found a relatively higher proportion of patients with the following characteristics; younger, rectum as primary tumor location, the signet, and mucinous histology, higher incidence of peritoneum involvement. The routine use of targeted therapies is limited. Government schemes (inclusion of targeted therapies in the Ayushman scheme), NGO assistance, and availability of generic low-cost targeted drugs may increase the availability.
Literature
4.
go back to reference Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):44–70.CrossRef Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):44–70.CrossRef
7.
go back to reference Deo SV, Shukla NK, Srinivas G, Mohanti BK, Raina V, Sharma A, et al. Colorectal cancers--experience at a regional cancer Centre in India. Trop Gastroenterol Off J Dig Dis Found. 2001;22(2):83–6. Deo SV, Shukla NK, Srinivas G, Mohanti BK, Raina V, Sharma A, et al. Colorectal cancers--experience at a regional cancer Centre in India. Trop Gastroenterol Off J Dig Dis Found. 2001;22(2):83–6.
8.
go back to reference Deo S, Kumar S, Shukla NK, Kar M, Mohanti BK, Sharma A, et al. Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center. Indian J Cancer. 2004;41(3):120–4.PubMed Deo S, Kumar S, Shukla NK, Kar M, Mohanti BK, Sharma A, et al. Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center. Indian J Cancer. 2004;41(3):120–4.PubMed
16.
go back to reference Mukherji A, Rathi AK, Sharma K, Kumar V, Singh K, Bahadur AK. A study on presentation and behavior of Colo-rectal carcinoma in young Indian patients. Trop Gastroenterol Off J Dig Dis Found. 2011;32(2):122–7. Mukherji A, Rathi AK, Sharma K, Kumar V, Singh K, Bahadur AK. A study on presentation and behavior of Colo-rectal carcinoma in young Indian patients. Trop Gastroenterol Off J Dig Dis Found. 2011;32(2):122–7.
18.
go back to reference Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and Leucovorin as first-line treatment for metastatic colorectal Cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.CrossRef Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and Leucovorin as first-line treatment for metastatic colorectal Cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.CrossRef
19.
go back to reference Jauhri M, Bhatnagar A, Gupta S, BP M, Minhas S, Shokeen Y, et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing–based cohort study. Tumor Biol. 2017;39(2):1010428317692265. https://doi.org/10.1177/1010428317692265.CrossRef Jauhri M, Bhatnagar A, Gupta S, BP M, Minhas S, Shokeen Y, et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing–based cohort study. Tumor Biol. 2017;39(2):1010428317692265. https://​doi.​org/​10.​1177/​1010428317692265​.CrossRef
24.
go back to reference Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):136–47. https://doi.org/10.1200/JCO.2000.18.1.136.CrossRef Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):136–47. https://​doi.​org/​10.​1200/​JCO.​2000.​18.​1.​136.CrossRef
27.
go back to reference Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol Off J Eur Soc Med Oncol. 2002;13(2):308–17. https://doi.org/10.1093/annonc/mdf034.CrossRef Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol Off J Eur Soc Med Oncol. 2002;13(2):308–17. https://​doi.​org/​10.​1093/​annonc/​mdf034.CrossRef
28.
go back to reference Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal Cancer treated with 5-fluorouracil—based chemotherapy. Clin Colorectal Cancer. 2003;2(4):231–4. https://doi.org/10.3816/CCC.2003.n.004.CrossRefPubMed Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal Cancer treated with 5-fluorouracil—based chemotherapy. Clin Colorectal Cancer. 2003;2(4):231–4. https://​doi.​org/​10.​3816/​CCC.​2003.​n.​004.CrossRefPubMed
31.
go back to reference Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(36):9441–2. https://doi.org/10.1200/JCO.2005.04.4792.CrossRef Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(36):9441–2. https://​doi.​org/​10.​1200/​JCO.​2005.​04.​4792.CrossRef
32.
go back to reference Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392. https://doi.org/10.1001/jama.2017.7105. Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392. https://​doi.​org/​10.​1001/​jama.​2017.​7105.
35.
37.
go back to reference Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of Cetuximab with continuous or intermittent fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal Cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62. https://doi.org/10.1200/JCO.2011.38.0915.CrossRefPubMed Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of Cetuximab with continuous or intermittent fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal Cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62. https://​doi.​org/​10.​1200/​JCO.​2011.​38.​0915.CrossRefPubMed
Metadata
Title
Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center
Authors
Vinod Sharma
Atul Sharma
Vinod Raina
Deepak Dabkara
Bidhu Kalyan Mohanti
N. K. Shukla
Sushmita Pathy
Sanjay Thulkar
S. V. S. Deo
Sunil Kumar
Ranjit Kumar Sahoo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08398-z

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine